{"organizations": [], "uuid": "cbe2362ff388087f1021f7857f272c5ea65cf4ef", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-poxel-and-roivant-announce-strateg/brief-poxel-and-roivant-announce-strategic-agreement-for-development-and-commercialization-of-imeglimin-idUSFWN1Q208N", "country": "US", "domain_rank": 408, "title": "BRIEF-Poxel And ‍Roivant Announce Strategic Agreement For Development And Commercialization Of Imeglimin", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.026, "site_type": "news", "published": "2018-02-12T15:12:00.000+02:00", "replies_count": 0, "uuid": "cbe2362ff388087f1021f7857f272c5ea65cf4ef"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-poxel-and-roivant-announce-strateg/brief-poxel-and-roivant-announce-strategic-agreement-for-development-and-commercialization-of-imeglimin-idUSFWN1Q208N", "ord_in_thread": 0, "title": "BRIEF-Poxel And ‍Roivant Announce Strategic Agreement For Development And Commercialization Of Imeglimin", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "dainippon pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - POXEL SA:\n* ‍ROIVANT AND POXEL ANNOUNCE STRATEGIC AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN IN U.S., EUROPE, AND ADDITIONAL COUNTRIES WORLDWIDE​\n* ‍ROIVANT TO CONCURRENTLY INVEST $15 MILLION (APPROXIMATELY EUR 12 MILLION) IN POXEL THROUGH SUBSCRIPTION TO NEWLY-ISSUED ORDINARY SHARES AT EUR 8.5 PER SHARE​\n* ‍TO RECEIVE UPFRONT PAYMENT OF $35 MILLION​ * ‍POXEL TO CONTRIBUTE $25 MILLION (APPROXIMATELY EUR 20 MILLION) TO DEVELOPMENT PROGRAM​\n* ‍ROIVANT WILL BE RESPONSIBLE FOR IMEGLIMIN‘S DEVELOPMENT AND COMMERCIALIZATION IN U.S., EUROPE, AND OTHER COUNTRIES OUTSIDE OF POXEL‘S PARTNERSHIP WITH SUMITOMO DAINIPPON PHARMA​\n* ‍TO RECEIVE UPFRONT PAYMENT OF $35 MILLION, POTENTIAL FUTURE DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS AND SALES-BASED PAYMENTS OF UP TO $600 MILLION, AND DOUBLE-DIGIT ROYALTIES ON NET SALES​\n* ‍PARTIES WILL DECIDE ON A POTENTIAL CO-PROMOTION PRIOR TO COMMERCIALIZATION​\n* ‍POXEL TO RECEIVE UPFRONT PAYMENT OF $35 MILLION, POTENTIAL FUTURE DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS AND SALES-BASED PAYMENTS OF UP TO $600 MILLION, AND DOUBLE-DIGIT ROYALTIES ON NET SALES​\n* SEES THE INITIATION OF PHASE 3 PROGRAM IN U.S. AND EUROPE IN 2019​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T15:12:00.000+02:00", "crawled": "2018-02-13T15:41:00.025+02:00", "highlightTitle": ""}